Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies
August 23rd 2024Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.
Assessing FLAURA2's Influence: How Has It Shaped Your First-Line Treatment Strategy?
August 23rd 2024Following the 2024 ASCO Annual Meeting, medical oncologists share insights on how the availability of the FLAURA2 treatment regimen has impacted the treatment of patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC).
Starting CML Treatment: Collaborative Choices for Better Outcomes
August 22nd 2024Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies that optimize communication when considering treatment options.